Drugs / SQ001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04026321 | Oct → Dec 2018 | refractory malignant neoplasm | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQ-001 | “Subjects will be allocated 1:4 to receive an infusion of saline control (0.9% saline for injection) or Shenqi Fuzheng Injection(SQ-001) continuously for about 1-4 hours.” NCT04026321 ↗ |
| Known as | Shenqi Fuzheng Injection | “Subjects will be allocated 1:4 to receive an infusion of saline control (0.9% saline for injection) or Shenqi Fuzheng Injection(SQ-001) continuously for about 1-4 hours.” NCT04026321 ↗ |
| Route | Intravenous | “SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute” NCT04026321 ↗ |